In this free webinar, discover the benefits of using specialized contract research organizations (CROs) to propel biopharma drug development pipelines within the necessary timelines, budgets and scientific goals. Attendees will learn from real-life case studies of issues faced by emerging biopharma and be introduced to solutions put forth by specialized CROs. The featured speakers will explore improved models for bioanalytical outsourcing early-on to avoid costly issues or delays in the later stages of drug development.
TORONTO, June 17, 2024 /PRNewswire-PRWeb/ -- After approaching a clinical research organization (CRO), does prioritization or working with the "A team" seem to be missing? Are turnaround times for sample analysis longer than anticipated?
Emerging biopharma and biotech often face several difficulties when outsourcing to generalized large CROs. However, a few tailored strategies can be deployed to avoid such hurdles and find specialized CRO partners that are a better fit for small- to mid-size companies.
Emerging biopharma have unique needs due to perhaps the level of resources and personnel capacity available or the funding and regulatory experience at hand. The traditional model of outsourcing has primarily evolved around the needs of large pharma over the past decades; owing to the growth in emerging biopharma today, the CRO–drug developer relationship needs to modernize and adapt to better serve small- to mid-size companies.
During this webinar, the panel will delve into the benefits of building specialized CRO partnerships for emerging biopharma and biotech. Various commonly faced hurdles will be analyzed to understand how R&D and drug development teams can rethink their outsourcing processes in the early stages to avoid issues in the future.
The increasing trend of outsourced testing across the pharmaceuticals industry is well known and shows no signs of abatement. So, the value driven by this model of drug development should not exclude small- to mid-size companies. The panelists will examine how to use outsourcing to speed up timelines, work within budgets and gain access to valuable scientific and regulatory experience.
Register for this webinar today to gain insights into effective outsourcing strategies tailored for emerging biopharma and biotech companies.
Join Anitha Krishnan, PhD, Sr. Director/Head of Biology, Aviceda Therapeutics, R. John Stubbs, PhD, Principal & CEO, Stubbs & Hensel Pharma Consulting, LLC; and Charles Zogzas, PhD, SVP Business Development, Sannova Analytical, for the live webinar on Friday, June 28, 2024, at 1pm EDT (6pm BST/UK).
For more information, or to register for this event, visit Rethinking Emerging Biopharma's Relationships with CROs.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Soumya Shashikumar, Xtalks, +1 (416) 977-6555 x371, [email protected], http://xtalks.com
SOURCE Xtalks
Share this article